Avodarti caps 0.5mg #30 /TR/
Avodarti caps 0.5mg #30 /TR/

Avodarti caps 0.5mg #30 /TR/

პოლონეთი

გლაქსოსმიტკლაინი

Avodart capsules 0.5 mg are used for the treatment of benign prostatic hyperplasia.

About Product

Avodart capsule 0.5 mg

Composition:

Active ingredient – Dutasteride 0.5 mg (per capsule)


Indications:

Used for the treatment of benign prostatic hyperplasia (BPH) — to reduce the size of the enlarged prostate, improve urinary flow, and lower the risk of acute urinary retention and the need for surgical intervention.


Dosage and Administration:

The recommended dose for adult men (including elderly patients) is 0.5 mg (1 capsule) once daily.
The capsule should be swallowed whole, without chewing or opening.
Food does not affect the absorption of the drug.

Although some improvement may be noticed early, treatment should be continued for at least 6 months to accurately assess its effectiveness.

No dose adjustment is necessary in patients with renal impairment (as less than 0.1% of the drug is excreted in the urine).
Use with caution in patients with hepatic impairment, as dutasteride undergoes extensive liver metabolism and has a half-life of approximately 3 to 5 days.


Side Effects:

Reproductive system:

  • Erectile dysfunction

  • Decreased libido

  • Ejaculation disorders

  • Gynecomastia (breast enlargement or tenderness in men)

Allergic reactions:

  • In rare cases: rash, urticaria (hives), localized swelling


Contraindications:

  • Hypersensitivity to dutasteride or any of the excipients

  • Hypersensitivity to other 5-alpha reductase inhibitors

  • Contraindicated in women and children

Show More
More Info
Brand
გლაქსოსმიტკლაინი
Country
პოლონეთი
Generic
dutasterid
Dose
0.5მგ
Form
კაფსულა
Quantity
30
Contact Us
(032) 2 40 00 04
digitalsupport@gepha.com
info@gepha.com
JSC Gepha, ID 201991229
24A Sulkhan Tsintsadze Street 0160, Tbilisi, Georgia
Download
Application is available on Android and iOS systems
©2025. PHARMADEPOT. All rights reserved
powered by
In case of side effects and complaints about the drugs, please contact us by email:pharmacovigilance@gepha.com
Home
Cart
My Page